PMID- 15572595
OWN - NLM
STAT- MEDLINE
DCOM- 20060707
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 105
IP  - 6
DP  - 2005 Mar 15
TI  - Imatinib mesylate therapy may overcome the poor prognostic significance of 
      deletions of derivative chromosome 9 in patients with chronic myelogenous 
      leukemia.
PG  - 2281-6
AB  - Deletions of derivative chromosome 9 [der(9)] can be identified by fluorescence 
      in situ hybridization (FISH) in 10% to 15% of patients with chronic myeloid 
      leukemia (CML). Patients with der(9) deletions have been reported to have an 
      adverse outcome when treated with chemotherapy, interferon, and possibly imatinib 
      mesylate. We investigated the frequency and prognostic significance of der(9) 
      deletions among 352 patients with CML treated with imatinib mesylate at our 
      institution, in whom a deletion status of der(9) was determined. Thirty-three 
      patients (9%; 95% CI 0.07, 0.13) (30 in chronic phase, 3 in accelerated phase) 
      had der(9) deletions. The rates of major (82% vs 79%, P = 0.82) and complete 
      cytogenetic response (76% vs 66%, P = .33) with imatinib mesylate therapy were 
      similar in patients with and without der(9) deletions, respectively. After a 
      median follow-up of 28 months, there was no difference in overall survival (P = 
      .30) or response duration (P = .49) in patients with and without deletions. In a 
      multivariate analysis, der(9) deletions had no significant impact on response, 
      survival, or response duration. We conclude that treatment with imatinib mesylate 
      overcomes the adverse prognostic significance of der(9) deletions in patients 
      with CML.
FAU - Quintas-Cardama, Alfonso
AU  - Quintas-Cardama A
AD  - Department of Leukemia, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 
      428, Houston, TX 77030, USA.
FAU - Kantarjian, Hagop
AU  - Kantarjian H
FAU - Talpaz, Moshe
AU  - Talpaz M
FAU - O'Brien, Susan
AU  - O'Brien S
FAU - Garcia-Manero, Guillermo
AU  - Garcia-Manero G
FAU - Verstovsek, Srdan
AU  - Verstovsek S
FAU - Rios, Mary Beth
AU  - Rios MB
FAU - Hayes, Kimberly
AU  - Hayes K
FAU - Glassman, Armand
AU  - Glassman A
FAU - Bekele, B Nebiyou
AU  - Bekele BN
FAU - Zhou, Xian
AU  - Zhou X
FAU - Cortes, Jorge
AU  - Cortes J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
DEP - 20041130
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Benzamides
MH  - *Chromosome Deletion
MH  - *Chromosomes, Human, Pair 9
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Imatinib Mesylate
MH  - In Situ Hybridization, Fluorescence
MH  - Interferons/administration & dosage/adverse effects
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/genetics/mortality
MH  - Male
MH  - Middle Aged
MH  - Piperazines/*administration & dosage/adverse effects
MH  - Pyrimidines/*administration & dosage/adverse effects
MH  - Remission Induction
MH  - Treatment Outcome
EDAT- 2004/12/02 09:00
MHDA- 2006/07/11 09:00
CRDT- 2004/12/02 09:00
PHST- 2004/12/02 09:00 [pubmed]
PHST- 2006/07/11 09:00 [medline]
PHST- 2004/12/02 09:00 [entrez]
AID - S0006-4971(20)45726-X [pii]
AID - 10.1182/blood-2004-06-2208 [doi]
PST - ppublish
SO  - Blood. 2005 Mar 15;105(6):2281-6. doi: 10.1182/blood-2004-06-2208. Epub 2004 Nov 
      30.